Pacira BioSciences (NASDAQ:PCRX) Earns “Buy” Rating from HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Pacira BioSciences (NASDAQ:PCRX – Free Report) in a research report sent to investors on Monday, Benzinga reports. They currently have a $57.00 price target on the stock. HC Wainwright also issued estimates for Pacira BioSciences’ Q1 2024 earnings at $0.38 EPS, Q2 2024 earnings at $0.51 […]
More Stories
How to Match Native Display Ads to Your Content and Campaign Goals
A native campaign can struggle when the ad attracts one kind of interest but the destination asks for something different....
491 Fugitives Hiding in Public Housing Arrested in Nationwide Sweep
By Naveen Athrappully A multi-month law enforcement operation has led to the arrests of 491 criminal fugitives living in government-assisted...
Trump Doubles Down on $5,000 Payments Tied to Midterm Results
By Jack Phillips President Donald Trump on Monday released a new advertisement that doubled down on his promise to send...
Zelenskyy Says Strikes on Russian Refineries Will Continue If Putin Rejects Energy Ceasefire
By Owen Evans Ukraine will continue its long-range strikes against Russia if Moscow doesn’t accept an energy truce, President Volodymyr...
Federal Agents Search Rep. Ilhan Omar’s Home: What We Know
By Jack Phillips The Washington home of Rep. Ilhan Omar (D-Minn.) was searched on Monday by federal agents as part...
Federal Agents Search Rep. Ilhan Omar’s Home: AP Report
By Zachary Stieber Federal agents on Oct. 12 searched the home of Rep. Ilhan Omar (D-Minn.) as part of a...